Compare TCMD & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | SLDB |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.4M | 498.6M |
| IPO Year | 2016 | 2017 |
| Metric | TCMD | SLDB |
|---|---|---|
| Price | $25.77 | $7.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $36.00 | $16.36 |
| AVG Volume (30 Days) | 303.2K | ★ 975.2K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.14 | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.34 | $2.61 |
| 52 Week High | $37.77 | $8.87 |
| Indicator | TCMD | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 45.74 |
| Support Level | $25.38 | $5.08 |
| Resistance Level | $26.65 | $7.35 |
| Average True Range (ATR) | 1.51 | 0.42 |
| MACD | 0.33 | -0.11 |
| Stochastic Oscillator | 74.43 | 25.78 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.